TheraVet: Launch of BIOCERA-VET® Canine Osteosarcoma Study Conducted by the Prestigious University of Florida
November 23 2023 - 1:30AM
Business Wire
- Study assessing the efficacy of BIOCERA-VET® Osteosarcoma
Cementoplasty associated with stereotactic radiotherapy1
- Evaluation of the effect on lameness and the risk of
pathological fracture
- University of Florida is ranked #7 among veterinary medical
colleges nationwide by U.S. News & World Report
Regulatory News:
TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in pets,
announces the launch of a clinical study assessing the efficacy
of BIOCERA-VET® Osteosarcoma Cementoplasty combined with
Stereotactic Radiotherapy (SRT) in patients with osteosarcoma.
The study will be led by Dr Marilia Takada (DVM, PhD, DACVR
Radiation Oncology, Assistant Professor and Radiation Oncology
Service chief, and by Dr Judith Bertran (DVM, MRCVS, DACVS (SA),
ACVS Fellow in Surgical Oncology) Assistant Professor and Surgical
Oncology Service Chief at the University of Florida.
Canine osteosarcoma is commonly treated by limb amputation for
local tumor control, and adjuvant chemotherapy to delay the onset
of metastases. Standard limb-sparing surgery, used as alternative
to amputation, suffers from high complication rates and is only
suitable at specific locations; therefore, novel limb-sparing
technique options are currently more and more sought-after as an
alternative to amputation.
A promising alternative to the previous limb-sparing
techniques is percutaneous cementoplasty. This procedure consists
in a percutaneous injection of a bone cement - such as BIOCERA-VET®
Osteosarcoma - into the bone tumor site thus
providing analgesia, bone consolidation, and preventing
pathological fractures2. This procedure can be
combined with ablation techniques, with adjuvant chemotherapy,
and/or radiation therapy. Among the latter, SRT, while acting on
tumor’s cells and locally controlling the progression of the tumor
and improving lameness, is associated with a high rate of
pathological fracture (41%) due to bone weakening3. The combination
of SRT with percutaneous cementoplasty could therefore be an option
to counteract the consequences of the radiotherapy by strengthening
the bone.
In this context, a study assessing the combination of
percutaneous cementoplasty and SRT in 10 dogs suffering from
appendicular osteosarcoma will be conducted by Dr Marilia Takada
and by Dr Judith Bertran at the University of Florida.
The dogs will be treated by SRT followed two weeks later by a
percutaneous cementoplasty using BIOCERA-VET® Osteosarcoma. The
objectives of the study will be to evaluate the effect on
lameness by using objective measurements (i.e., force plate
analysis) and to assess the risk of pathological fracture.
Patients will be followed monthly for the first 3 months and then
every three months until the patients end of the life. First
patient enrolment is expected in December 2023. With an estimated
enrolment phase of 6 months, the study will be conducted over a
period of 18 months, with first results expected in a year.
Dr. Judith Bertran, Assistant Professor and Surgical Oncology
Service Chief at the University of Florida, stated: “As
osteosarcoma is a devastating local and systemic disease,
investigation of new strategies to ensure local disease control and
comfort for our patients is imperative. As researchers, this pilot
study is extremely important to investigate the benefits of the
percutaneous cementoplasty in dogs undergoing SRT for osteosarcoma.
Collected data will serve as the basis of larger clinical trials to
investigate further the best protocols for SRT combined with
cementoplasty to preserve limb function, comfort level and
acceptable disease-free intervals and survivals for canine
patients.”
About the University of Florida Ranked #7 among
veterinary medical colleges nationwide by U.S. News & World
Report, University of Florida College of Veterinary Medicine
teaches the veterinarians of the future and provides leading-edge
care to animal patients from throughout the Southeast through the
UF Veterinary Hospitals. Its programs in biomedical research
advance the science of animal, human and environmental health.
About TheraVet SA TheraVet is a veterinary biotechnology
company specializing in osteoarticular treatments for companion
animals. The Company develops targeted, safe and effective
treatments to improve the quality of life of pets suffering from
joint and bone diseases. For pet owners, the health of their pets
is a major concern and TheraVet’s mission is to address the need
for innovative and curative treatments. TheraVet works closely with
international opinion leaders in order to provide a more effective
response to ever-growing needs in the field of veterinary medicine.
TheraVet is listed on Euronext Growth® Paris and Brussels, has its
head office in Belgium (Gosselies) with a US subsidiary. For more
information, visit the TheraVet website or follow us on LinkedIn /
Facebook / Twitter
About BIOCERA-VET In close collaboration with an
international scientific board, THERAVET® has developed a new line
of calcium-phosphate and biological bone substitutes, BIOCERA-VET®.
BIOCERA-VET® is a full range of innovative, easy-to-use, efficient
& cost-effective bone substitutes indicated in bone surgeries
where a bone graft is required and as a palliative alternative in
the management of canine osteosarcoma. Based on extremely promising
clinical results, this line offers the possibility of a better,
more convenient and more efficient orthopedic surgery.
- BIOCERA-VET® is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable
self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, an affordable biocompatible
calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable
calcium-phosphate bone substitute for cementoplasty
- BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic
delivery calcium-phosphate bone substitute
For more information, visit BIOCERA-VET website.
1 Stereotatic radiotherapy (SRT) is defined as focused radiation
beams targeting a well-defined tumor allowing high dose of
radiation at the tumor site and lower at the surrounding tissue. 2
Article under review 3 Wormhoudt Martin T et al. Outcome and
prognosis for canine appendicular osteosarcoma treated with
stereotactic body radiation therapy in 123 dogs. Vet Comp Oncol.
2021 June ; 19(2): 284–294. doi:10.1111/vco.12674
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231122957173/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@thera.vet Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
From Apr 2024 to May 2024
TheraVet (EU:ALVET)
Historical Stock Chart
From May 2023 to May 2024